Medidata, a subsidiary of Dassault Systèmes, and Project ALS have entered a research partnership in order to develop new therapeutic strategies for the treatment of Amyotrophic lateral sclerosis (ALS).

Also known as Lou Gehrig’s disease, ALS is a neurodegenerative disease closely related to Alzheimer’s, Parkinson’s, and Huntington’s diseases.

Under the partnership, Medidata will apply its artificial intelligence tools to aid the fight against ALS.

The research efforts will use Medidata’s Rave Omics, a biomarker discovery solution and part of company’s Acorn AI portfolio, which streamlines omic (including genomic, proteomic, and transcriptomic) data capture within the clinical study process.

Acorn AI was developed to focus on speeding up the development of analytics and AI solutions in clinical development.

Medidata co-founder and co-CEO Glen de Vries said: “We are proud to partner with Project ALS on such an important quest. The patients and the researchers inspire us, they are the basis of our mission to use technology to change lives.

“We look forward to applying Medidata’s next-generation tools to deepen our understanding of this devastating disease, and accelerate the pace of new discoveries.”

The agreement with Project ALS expands on the Medidata Institute’s programmes to advance precision medicine.

The new initiative is part of Medidata’s ongoing commitment to rare diseases.

Project ALS research advisory board member Neil Shneider said: “ALS is a complex, heterogeneous disease, and treatment of its various forms may require specific therapies targeting distinct ALS subtypes.

“I’m eager to begin working with Medidata’s Acorn AI team to define these subtypes, and to develop a precision medicine approach to our treatment of ALS.”

Medidata claims to have supported biopharma companies in conducting over 1,200 rare disease studies involving more than 190,000 patients.

The company’s Cloud-based platform allows clinical trials to run smoother, faster, and safer for patients.